BioSpace News Archive

Elekta announced that its MOSAIQ® Oncology Information System and Versa HD™ linear accelerator have been named “Best in KLAS” in the 2021 Best in KLAS: Software and Services Report.

The burgeoning scientific field of bioelectronic medicine, which features the use of electronic devices to stimulate nerves to treat disease, has shown great promise in alleviating serious health conditions.

-- Financing to support expanded partnering opportunities with life sciences, health systems, regulators and molecular labs -- -- Syapse committed to delivering real-world insights to improve outcomes for people with cancer

Biotech startup PercayAI and Saint Louis University (SLU) announced a partnership today to provide SLU researchers with access to PercayAI’s augmented intelligence (AI) drug discovery platform.

AccuVein Inc.( www.accuvein.com ), the leader in NIR vein visualization, today announced that the Infusion Nurses Society’s (INS) newly released 2021 Infusion Therapy Standards of Practice recommend use of NIR vein visualization technology

The study challenged mice with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified and the locomotor function, behavior, and cognition of the mice were evaluated.

The Analgesic Program started in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation.

Supply Clinic, the online marketplace for dental and healthcare supplies, announced the appointment of Dr. Patrick J Ferrillo, Jr., D.D.S., a leader in dental education and consolidation, to its Advisory Board.

Avinger, Inc. (NASDAQ:AVGR) (the a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the closing of an underwritten offering of 10,000,000 shares of common stock of the Company, at a price to the public of $1.44 per share.

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce it has signed a Collaborative Research Agreement with the University of British Columbia focussing on Major Depressive Disorder, often referred to as depression.